Mammary Cell News 8.37 September 22, 2016 | |
| |
TOP STORYThis study takes breast cancer as a model to understand mechanisms accounting for limited response of histone deacetylase (HDAC) inhibitors in solid tumors and to seek combination solutions. The authors discovered that feedback activation of leukemia inhibitory factor receptor signaling in breast cancer limits the response to HDAC inhibition [Cancer Cell] Abstract | Graphical Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)LABORATORY RESEARCHCancer-Cell-Biomimetic Nanoparticles for Targeted Therapy of Homotypic Tumors A unique biomimetic drug-delivery system composed of 4T1-breast-cancer-cell membranes and paclitaxel-loaded polymeric nanoparticles, demonstrates superior interactions to its source tumor cells and elongated blood circulation, and displays highly cell-specific targeting of the homotypic primary tumor and metastases, with successful inhibition of the growth and lung metastasis of the breast cancer cells. [Adv Mater] Abstract Researchers tested the hypothesis that leukemia inhibitory factor (LIF) provides a pro-dormancy signal to breast cancer cells in the bone. In breast cancer patients, LIF receptor (LIFR) levels are lower with bone metastases and are significantly and inversely correlated with patient outcome and hypoxia gene activity. [Nat Cell Biol] Abstract Local MicroRNA Delivery Targets Palladin and Prevents Metastatic Breast Cancer Scientists showed that breast cancer metastasis can be prevented by miR-96 or miR-182 treatment, and deciphered the mechanism of action. They found that miR-96/miR-182 downregulate Palladin protein levels, thereby reducing breast cancer cell migration and invasion. [Nat Commun] Full Article | Press Release Cytosine mutations within TCA/T motifs are common in cancer. A likely cause is the DNA cytosine deaminase APOBEC3B (A3B). However, A3B-null breast tumors still have this mutational bias. The authors showed that APOBEC3H haplotype I provides a likely solution to this paradox. [Nat Commun] Full Article | Press Release Researchers describe a mammary stem cell (MaSC) organoid-based approach for rapid generation of somatic genetically engineered mouse models (GEMMs). By using RNAi and CRISPR-mediated genome engineering in MaSC-GEMMs, they have discovered that inactivation of Ptpn22 or Mll3, two genes mutated in human breast cancer, greatly accelerated PI3K-driven mammary tumorigenesis. [Cell Rep] Full Article | Graphical Abstract Scientists discovered how backcross between a highly metastatic and low metastatic mouse strain identified Arntl2, a gene encoding a circadian rhythm transcription factor, as a metastasis susceptibility gene associated with progression, specifically in estrogen receptor-negative breast cancer patients. [PLoS Genet] Full Article Investigators identified a new molecular and functional network present in metastasis that regulates and coordinates with TrkC. They found that TrkC expression and clinical breast tumor pathological phenotypes show significant correlation. [Sci Rep] Full Article The ILC cell lines MDA-MB-134-VI, SUM44PE, and BCK4 were used to assess WNT4 gene expression and regulation, as well as the role of WNT4 in estrogen-regulated proliferation. [Breast Cancer Res] Abstract CLINICAL RESEARCHOmission of completion axillary lymph node dissection is a standard practice in patients with breast cancer and negative sentinel nodes (SNs) but has shown insufficient evidence to be recommended in those with SN invasion. [Eur J Cancer] Abstract | |
| |
REVIEWSTackling Breast Cancer Chemoresistance with Nano-Formulated SiRNA In this review, the authors focus on nanoformulation of siRNA for the fight against breast cancer chemoresistance. [Gene Ther] Abstract Visit our reviews page to see a complete list of reviews in the mammary cell research field. | |
| |
INDUSTRY NEWSPuma Biotechnology, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application for its lead product candidate PB272 (neratinib) for the extended adjuvant treatment of patients with early stage HER2-overexpressed/amplified breast cancer who have received prior adjuvant trastuzumab-based therapy. [Puma Biotechnology, Inc.] Press Release UCSF Researchers Awarded Breast Cancer Research Funding from Susan G. Komen Three UCSF researchers have been awarded $680,000 in grants from Susan G. Komen to support projects in breast cancer research. [UCSF] Press Release | |
| |
EVENTSNEW Global Forum on Transplantation Research and Technologies NEW Challenges, Solutions and Progress in Stem Cell Medicine Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Research Fellow – Breast Cancer Brain Metastasis (University of Leeds) Assistant Professor – Physiology and Biophysics (University of Illinois at Chicago) Postdoctoral Position or Internship – Cancer Research (Stanford University) Postdoctoral Researcher – Nuclear Medicine Dosimetry (University of Oxford) Postdoctoral Fellow – Rho GTPase Signaling in the Process of Breast Cancer (University of Leeds) Faculty Pathologist – Breast Pathology (University of California Los Angeles) Postdoctoral Researcher – Breast Cancer (Purdue University) Robert Stowell Chair – Experimental Pathology (University of California, Davis) Manager – Medical and Breast Imaging (Fred Hutchinson Cancer Research Center) Director Clinical Research – Medical Oncology (Fred Hutchinson Cancer Research Center) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Mammary Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|
Home Mammary Cell News Volume 8.37 | Sep 22 2016